Biofrontera (BFRI) Q2 2026 Earnings Report

The call conveyed strong operational and commercial momentum: double-digit revenue growth, substantial gross margin expansion, marked improvement in adjusted EBITDA, and clear near-term clinical catalysts (sBCC PDUFA and AK label expansion) that leverage the existing installed base. Key risks include an adverse ITC ruling temporarily restricting sales to accounts with the RhodoLED XL (affecting a meaningful minority of lamps), the need for border approval of a remedial lamp design, and a modest cash position with a going concern disclosure that may require additional financing. On balance, the positive operational trends and pipeline catalysts outweigh the near-term legal and liquidity headwinds, but successful remediation, timely approvals, and working capital execution remain critical.

Management guided that Biofrontera expects to achieve cash‑flow breakeven in 2026 while maintaining its full‑year revenue objectives (not quantified on the call), and highlighted near‑term regulatory and commercial milestones: a PDUFA target date of September 28, 2026 for superficial BCC with a planned full launch in Q1 2027, a supplemental NDA filing for AK on extremities/neck/trunk around end‑Q3 2026 with anticipated approval in Q3 2027, and progression of an acne program toward later‑stage trials; they noted the ITC exclusion order on the RhodoLED XL should affect timing more than total demand, remediation costs are estimated at roughly $0.5M (recorded in Q1), the non‑infringing XL will be submitted via a CBE‑30, and the company may tap a $1M XEPI milestone and/or a working‑capital facility if needed. Key operating and financial metrics cited to support guidance included Q2 product revenue of $12.0M (+32.9% YoY) and H1 revenue of $22.1M (+25.4%), Q2 Ameluz unit sales of 33,300 tubes (vs ~25,300 a year ago, ~30% unit growth), an installed base of ~801 lamps across ~740 offices (≈243 XLs), Q2 gross margin ~80% (vs ~71% prior year), Q2 adjusted EBITDA essentially breakeven (~‑$0.2M vs ‑$5.1M prior) and H1 adjusted EBITDA ‑$3.7M (vs ‑$9.5M), Q2 net loss $0.6M ($0.05/sh) vs $5.3M ($0.57/sh) prior, cash of $4.7M at 6/30/26 (vs $6.4M at 12/31/25), H1 operating cash used $1.7M (down from $7.2M), H1 order count +18.6%, average tubes per order +10%, 81% of large pre‑price‑increase customers reordered with their volume +41%, 66 net new accounts in H1 (vs 69), and inside sales contribution of ~1,070 tubes (whitespace) +920 tubes (vacant territories) in H1.